FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria

Oct 1, 2025 - 03:00
 0  0
EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0